{"entity":{"id":"2000","kind":"year","name":"2000 in oncology","aka":["2000"],"tldr":"Everything OnCo dates to 2000: 82 entries, 25 landmarks, 13 companies founded, 11 papers and 11 papers listed on people's pages. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"82 dated entries in OnCo fall in 2000: 25 landmarks, 13 companies founded, 11 papers, 11 papers listed on people's pages, 8 journals founded, 7 technologies, 5 approvals, 1 law or regulation and 1 regulatory event.\n\nOf those, 1 to the day and 81 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["1999","2001"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2000,"events":[{"group":"approval","date":"2000","precision":"year","title":"Arsenic trioxide approved in US","note":"Relapsed/refractory APL","from":"arsenic-trioxide","refs":[]},{"group":"approval","date":"2000","precision":"year","title":"Fludeoxyglucose F-18 (FDG) approved in US","note":"Oncology: assessment of abnormal glucose metabolism to assist in evaluating malignancy","from":"fludeoxyglucose-f18","refs":[]},{"group":"approval","date":"2000","precision":"year","title":"Gemtuzumab ozogamicin approved in US","note":"Relapsed CD33+ AML (withdrawn 2010)","from":"gemtuzumab-ozogamicin","refs":[]},{"group":"approval","date":"2000","precision":"year","title":"Thyrotropin alfa approved in EU","note":"Thyroglobulin testing and radioiodine imaging in thyroid cancer follow-up; pre-therapeutic stimulation for radioiodine ablation","from":"thyrotropin-alfa","refs":[]},{"group":"approval","date":"2000","precision":"year","title":"Triptorelin approved in US","note":"Palliative treatment of advanced prostate cancer","from":"triptorelin","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Achieve Life Sciences (formerly OncoGenex) founded","note":"Bothell, WA","from":"achieve-life-sciences","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Biocon Biologics founded","note":"Bengaluru","from":"biocon-biologics","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Children's Oncology Group (COG) founded","note":"Monrovia, CA","from":"childrens-oncology-group","refs":[]},{"group":"company","date":"2000","precision":"year","title":"General Catalyst founded","note":"Cambridge, MA","from":"general-catalyst","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Hutchmed founded","note":"Hong Kong / Shanghai","from":"hutchmed","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Immunitor founded","note":"Ulaanbaatar","from":"immunitor","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Immunovaccine (IMV) founded","note":"Halifax, Nova Scotia","from":"immunovaccine","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Lightspeed Venture Partners founded","note":"Menlo Park, CA","from":"lightspeed-venture-partners","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Lux Capital founded","note":"New York, NY","from":"lux-capital","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Merrimack Pharmaceuticals founded","note":"Cambridge, MA","from":"merrimack-pharmaceuticals","refs":[]},{"group":"company","date":"2000","precision":"year","title":"Modulight founded","note":"Tampere","from":"modulight","refs":[]},{"group":"company","date":"2000","precision":"year","title":"West Japan Oncology Group founded","note":"Osaka","from":"wjog","refs":[]},{"group":"company","date":"2000","precision":"year","title":"WuXi AppTec founded","note":"Shanghai","from":"wuxi-apptec","refs":[]},{"group":"history","date":"2000","precision":"year","title":"Arsenic trioxide approved for relapsed APL","note":"Acute promyelocytic leukaemia","from":"apl","refs":["arsenic-trioxide"]},{"group":"history","date":"2000","precision":"year","title":"Autologous transplant standard for relapse; late-effects registries reveal cardiac and second-cancer burden","note":"Hodgkin lymphoma","from":"hodgkin-lymphoma","refs":["autologous-stem-cell-transplant","cardio-oncology"]},{"group":"history","date":"2000","precision":"year","title":"COG Rare Tumors committee established","note":"Rare cancers of childhood (NCI PDQ umbrella). Creates a registry and protocols for infrequent tumours.","from":"rare-childhood-cancers","refs":[]},{"group":"history","date":"2000","precision":"year","title":"Concurrent cisplatin chemoradiation becomes standard for locally advanced disease","note":"Head and neck squamous cell carcinoma. Meta-analysis (MACH-NC) confirms ~6.5% absolute survival gain.","from":"head-and-neck","refs":["imrt-igrt","platinum"]},{"group":"history","date":"2000","precision":"year","title":"Döhner hierarchical FISH model","note":"Chronic lymphocytic leukaemia. del(17p) and del(11q) adverse; del(13q) favourable.","from":"cll","refs":["cytogenetics-fish","del17p-tp53"]},{"group":"history","date":"2000","precision":"year","title":"Endoscopic endonasal resection of sinonasal cancer established","note":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma). Series from Pittsburgh and Europe show equivalence to open surgery.","from":"sinonasal","refs":[]},{"group":"history","date":"2000","precision":"year","title":"Endoscopic submucosal dissection developed in Japan","note":"Early gastric cancer","from":"early-gastric-cancer","refs":["endoscopic-resection"]},{"group":"history","date":"2000","precision":"year","title":"FIGO 2000 staging and prognostic score","note":"Gestational trophoblastic neoplasia","from":"gestational-trophoblastic","refs":[]},{"group":"history","date":"2000","precision":"year","title":"FIGO adopts the combined anatomical stage and prognostic score","note":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","from":"low-risk-gtn","refs":["staging-systems"]},{"group":"history","date":"2000","precision":"year","title":"FIGO combines anatomical stage and prognostic score","note":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","from":"high-risk-gtn","refs":["staging-systems"]},{"group":"history","date":"2000","precision":"year","title":"First 90Y- and 177Lu-DOTATOC/DOTATATE PRRT series (Rotterdam, Basel)","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":["prrt"]},{"group":"history","date":"2000","precision":"year","title":"Gemtuzumab ozogamicin, the first ADC","note":"Acute myeloid leukaemia. Accelerated approval in relapsed CD33+ AML; withdrawn 2010 after SWOG S0106 toxicity.","from":"aml","refs":["gemtuzumab-ozogamicin"]},{"group":"history","date":"2000","precision":"year","title":"Gemtuzumab: first ADC","note":"Acute myeloid leukaemia","from":"aml","refs":["gemtuzumab-ozogamicin"]},{"group":"history","date":"2000","precision":"year","title":"Gene-expression profiling defines GCB and ABC subtypes","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["cell-of-origin"]},{"group":"history","date":"2000","precision":"year","title":"Gillison links HPV16 to a distinct subset of oropharyngeal cancers","note":"HPV-positive oropharyngeal cancer","from":"hpv-positive-oropharyngeal-cancer","refs":[]},{"group":"history","date":"2000","precision":"year","title":"HPV linked to oropharyngeal cancer","note":"Oropharyngeal cancer (tonsil and base of tongue). Gillison and colleagues show HPV16 in a distinct subset of tumours.","from":"oropharyngeal-cancer","refs":[]},{"group":"history","date":"2000","precision":"year","title":"Imatinib transforms Ph-positive leukaemia","note":"Acute lymphoblastic leukaemia. First BCR::ABL1 inhibitor; Ph+ ALL survival doubles when added to chemotherapy.","from":"all-leukemia","refs":["imatinib","bcr-abl"]},{"group":"history","date":"2000","precision":"year","title":"Imatinib: dramatic response in a single GIST patient (Joensuu, NEJM 2001)","note":"Gastrointestinal stromal tumour (GIST)","from":"gist","refs":["imatinib"]},{"group":"history","date":"2000","precision":"year","title":"Irinotecan and oxaliplatin combinations","note":"Colorectal cancer. FOLFIRI and FOLFOX double median metastatic survival from ~12 to ~20 months.","from":"colorectal","refs":["folfox","folfiri"]},{"group":"history","date":"2000","precision":"year","title":"Molecular portraits define the basal-like subtype","note":"Triple-negative breast cancer (TNBC). Perou and Sørlie's expression profiling separates basal-like from luminal breast cancers.","from":"tnbc","refs":["rna-seq"]},{"group":"history","date":"2000","precision":"year","title":"Molecular subtypes described","note":"Breast cancer (all types). Perou and Sorlie's expression profiling defines luminal, HER2-enriched and basal-like breast cancers.","from":"breast-cancer","refs":["basal-like","pam50"]},{"group":"history","date":"2000","precision":"year","title":"PAX8-PPARG fusion discovered","note":"Follicular thyroid cancer","from":"follicular-thyroid-cancer","refs":[]},{"group":"history","date":"2000","precision":"year","title":"Rituximab in PTLD","note":"Post-transplant lymphoproliferative disorder (PTLD). Case series and the French multicentre trial (Blood 2006) establish anti-CD20 therapy.","from":"post-transplant-lymphoproliferative-disorder","refs":["rituximab"]},{"group":"history","date":"2000","precision":"year","title":"SDHD mutations found in familial head and neck paraganglioma; SDHB follows in 2001","note":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","from":"hereditary-ppgl","refs":["sdh-deficiency"]},{"group":"history","date":"2000","precision":"year","title":"SDHD mutations in hereditary paraganglioma","note":"Pheochromocytoma and paraganglioma (PPGL). Baysal and colleagues, Science: metabolic enzyme genes as tumour suppressors.","from":"pheochromocytoma-paraganglioma","refs":[]},{"group":"journal","date":"2000","precision":"year","title":"Asian Pacific journal of cancer prevention founded","note":"Asian Pacific Organization for Cancer Prevention (APOCP), hosted by the West Asia Organization for Cancer Prevention","from":"asian-pacific-journal-of-cancer-prevention","refs":[]},{"group":"journal","date":"2000","precision":"year","title":"Cancer imaging founded","note":"BMC (Springer Nature)","from":"cancer-imaging","refs":[]},{"group":"journal","date":"2000","precision":"year","title":"Cancer research and treatment founded","note":"Korean Cancer Association","from":"cancer-research-and-treatment","refs":[]},{"group":"journal","date":"2000","precision":"year","title":"Clinical breast cancer founded","note":"Elsevier","from":"clinical-breast-cancer","refs":[]},{"group":"journal","date":"2000","precision":"year","title":"Current treatment options in oncology founded","note":"Springer","from":"current-treatment-options-in-oncology","refs":[]},{"group":"journal","date":"2000","precision":"year","title":"Familial cancer founded","note":"Springer","from":"familial-cancer","refs":[]},{"group":"journal","date":"2000","precision":"year","title":"The cancer journal founded","note":"Wolters Kluwer (Lippincott Williams & Wilkins)","from":"the-cancer-journal","refs":[]},{"group":"journal","date":"2000","precision":"year","title":"The Lancet Oncology founded","note":"Elsevier","from":"lancet-oncology","refs":[]},{"group":"law","date":"2000","precision":"year","title":"Regulation (EC) No 141/2000: EU orphan medicines","note":"European Union, regulation.","from":"eu-orphan-regulation","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"A quantitative model for differential motility of gliomas in grey and white matter","note":"Swanson KR, Alvord EC, Murray JD. Cell proliferation.","from":"paper-swanson-cell-prolif","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial.","note":"van der Zee J, González González D, van Rhoon GC, et al. The Lancet.","from":"paper-van-der-zee-lancet","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","note":"Alizadeh AA, Eisen MB, Davis RE, et al. Nature.","from":"paper-alizadeh-nature","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer","note":"Górski B, Byrski T, Huzarski T, et al. American Journal of Human Genetics.","from":"paper-gorski-brca1-founder-mutations-poland-ajhg-2000","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"Incidence of lymph node metastasis from early gastric cancer: estimation from 5,265 patients at two large centres","note":"Gotoda T, Yanagisawa A, Sasako M, et al. Gastric cancer.","from":"paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"Molecular portraits of human breast tumours","note":"Perou CM, Sørlie T, Eisen MB, et al. Nature.","from":"paper-perou-molecular-portraits-breast-tumours-nature-2000","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies","note":"Peto R, Darby S, Deo H, et al. BMJ.","from":"paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"Stojdl 2000: cancer cells that stopped answering interferon cannot stop a virus either","note":"Stojdl DF, Lichty B, Knowles S, et al. Nature Medicine.","from":"paper-stojdl-vsv-interferon-defect-natmed-2000","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"The Hallmarks of Cancer: six capabilities every tumour must acquire","note":"Hanahan D, Weinberg RA. Cell.","from":"paper-hallmarks-of-cancer-cell-2000","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"Therasse 2000: RECIST, the standard rules for measuring whether a tumour responds","note":"Therasse P, Arbuck SG, Eisenhauer EA, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-therasse-recist-jnci-2000","refs":[]},{"group":"paper","date":"2000","precision":"year","title":"Vogelstein, Lane and Levine 2000: surfing the p53 network","note":"Vogelstein B, Lane D, Levine AJ. Nature.","from":"paper-vogelstein-surfing-p53-network-nature-2000","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"A chemical switch for inhibitor-sensitive alleles of any protein kinase","note":"Nature","from":"kevan-shokat","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"Aphasia, depression, and non-verbal cognitive impairment in ischaemic stroke","note":"Cerebrovasc Dis","from":"juha-korpelainen","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","note":"Journal of Infectious Diseases","from":"denise-galloway","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis","note":"Oncogene","from":"claus-belka","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis","note":"New England Journal of Medicine","from":"chak-sing-lau","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","note":"Journal of Experimental Medicine","from":"gordon-freeman","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","note":"Nature Medicine","from":"john-bell","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"Incidental Prostate Cancer: The Importance of Complete Prostatic Removal at Cystoprostatectomy for Bladder Cancer","note":"Urologia Internationalis","from":"farhat-abbas","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","note":"JCO","from":"aimery-de-gramont","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"Prevalence and significance of low 25-hydroxyvitamin D concentrations in healthy subjects in Delhi","note":"American Journal of Clinical Nutrition","from":"nikhil-tandon","refs":[]},{"group":"person-paper","date":"2000","precision":"year","title":"The Founder Mutations in the BRCA1 , BRCA2 , and ATM Genes in Moroccan Jewish Women with Breast Cancer","note":"Genetic Testing","from":"yitshak-kreiss","refs":[]},{"group":"technology","date":"2000","precision":"year","title":"Antibody-drug conjugate (ADC)","note":"First use in humans or first approval, as the technology record states it.","from":"adc","refs":[]},{"group":"technology","date":"2000","precision":"year","title":"Patient positioning and surface guidance systems (AlignRT, Catalyst, ExacTrac Dynamic)","note":"First use in humans or first approval, as the technology record states it.","from":"patient-positioning-surface-guidance-systems","refs":[]},{"group":"technology","date":"2000","precision":"year","title":"Proliferation-invasion (reaction-diffusion) models of glioma","note":"First use in humans or first approval, as the technology record states it.","from":"reaction-diffusion-glioma-model","refs":[]},{"group":"technology","date":"2000","precision":"year","title":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","note":"First use in humans or first approval, as the technology record states it.","from":"quantitative-imaging-biomarkers","refs":[]},{"group":"technology","date":"2000","precision":"year","title":"Respiratory gating and tumour tracking systems (RPM, ABC, Calypso, Synchrony)","note":"First use in humans or first approval, as the technology record states it.","from":"respiratory-gating-tumour-tracking-systems","refs":[]},{"group":"technology","date":"2000","precision":"year","title":"Respiratory motion management (4D-CT, gating, breath-hold, tracking)","note":"First use in humans or first approval, as the technology record states it.","from":"respiratory-motion-management","refs":[]},{"group":"technology","date":"2000","precision":"year","title":"Surgical robots: da Vinci, Hugo, Versius and single-port systems","note":"First use in humans or first approval, as the technology record states it.","from":"surgical-robot-platforms","refs":[]},{"group":"regulatory","date":"2000-05-17","precision":"day","title":"Gemtuzumab ozogamicin: approval (US)","note":"Accelerated approval, relapsed CD33+ AML in older patients; first ADC ever approved","from":"gemtuzumab-ozogamicin","refs":[]}]},"route":"/years/2000/","neighbours":{"year":[{"id":"1999","kind":"year","name":"1999 in oncology","route":"/years/1999/"},{"id":"2001","kind":"year","name":"2001 in oncology","route":"/years/2001/"}]}}